Pharmacologic therapy for periocular infantile hemangiomas: A review of the literature

Seminars in Ophthalmology

Volumn 24, Issue 3, 2009, Pages 178-184

  Nguyen, John ^a   Fay, Aaron ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

Capillary hemangioma; Corticosteroids; Cyclophosphamide; Imiquimod; Infantile hemangioma; Interferon; Propranolol; Vincristine

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; BASIC FIBROBLAST GROWTH FACTOR; BETAMETHASONE DIPROPIONATE; BETAMETHASONE SODIUM PHOSPHATE; CORTICOSTEROID; CORTISONE; CYCLOPHOSPHAMIDE; CYTOCHROME B; DEXAMETHASONE; DIPROLENE AF; GAMMA INTERFERON; HEPARIN; HYDROCHLOROTHIAZIDE; HYDROCORTISONE; IMIQUIMOD; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; METHYLPREDNISOLONE; PREDNISONE; PROPRANOLOL; SOMATOMEDIN C; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VINCRISTINE; ALPHA INTERFERON; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; IMMUNOLOGIC FACTOR;

ABSENCE OF SIDE EFFECTS; ADRENAL SUPPRESSION; AMBLYOPIA; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTERY OCCLUSION; ASTIGMATISM; AUTONOMIC NEUROPATHY; BEHAVIOR CHANGE; BONE MARROW SUPPRESSION; CALCIFICATION; CAPILLARY HEMANGIOMA; CATARACT; CENTRAL RETINA ARTERY OCCLUSION; CEREBRAL PALSY; CONFUSION; CORTICOSTEROID THERAPY; CUSHINGOID SYNDROME; DRUG CHOICE; ERYTHEMA; EYE INJURY; EYELID DISEASE; FEVER; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; GONADAL DISEASE; GROWTH RETARDATION; HEADACHE; HEMORRHAGIC CYSTITIS; HUMAN; HYPERTENSION; HYPOPIGMENTATION; IMMUNOTHERAPY; INFECTION; INSOMNIA; INTRAOCULAR PRESSURE; IRRITABILITY; LIPOATROPHY; MALAISE; MALIGNANT NEOPLASTIC DISEASE; MOTOR DYSFUNCTION; MUSCLE HYPERTONIA; NEUTROPENIA; OPTIC NERVE DISEASE; PARALYSIS; PERIOCULAR HEMANGIOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETINA BLOOD VESSEL OCCLUSION; REVIEW; SIDE EFFECT; SKIN ATROPHY; SKIN DISEASE; SPASTICITY; STRABISMUS; TENDON REFLEX; TISSUE NECROSIS; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; CELL PROLIFERATION; DRUG EFFECT; FACE TUMOR; FEMALE; HEMANGIOMA; INFANT; NEWBORN; PREGNANCY;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-ANTAGONISTS; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CYCLOPHOSPHAMIDE; FACIAL NEOPLASMS; FEMALE; HEMANGIOMA; HUMANS; IMMUNOLOGIC FACTORS; INFANT; INFANT, NEWBORN; INTERFERON-ALPHA; PREGNANCY; PROPRANOLOL; VINCRISTINE;

EID: 67651152895     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.1080/08820530902805602     Document Type: Review

References (80)

1. Bruckner AL, Freiden, IJ. Hemangiomas of infancy. Journal of the American Academy of Dermatology 2003;48(4):477-496.
2. Goldberg NS, Rosanova MA. Periorbital hemangiomas. Dermatology Clinic 1992;10:653-661.
3. Schwartz SR, Blei F, Ceisler E, et al. Risk factors for amblyopia in children with capillary hemangiomas of the eyelids and orbit. Journal of AAPOS 2006;10:262-268.
4. Haik BG, Karcioglu ZA, Gordon RA, et al. Capillary hemangioma (infantile periocular hemangioma). Survey of Ophthalmology 1994;38:399-426.
5. Ritter R, Butschek RA, Friedlander M, et al. Pathogenesis of infantile hemangioma: New molecular and cellular insights. Expert Reviews in Molecular Medicine 2007;9(32):1-19.
6. Hoepfel-Kreiner I. Histogenesis of hemangiomas - An ultra-structural study on capillary and cavernous hemangiomas of the skin. Pathology, Research and Practice 1980;170:70-90.
7. Kraling BM, Razon MJ, Boon LM, et al. E-selectin is present in proliferating endothelial cells in human hemangiomas. The American Journal of Pathology 1996;148(4):1181-1191.
8. Ritter MR, Dorrell MI, Edmonds J, et al. Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proceedings of the National Academy of Sciences of the United States of America 2002;99(11):7455-7460.
9. Tan ST, Velikovic M, Ruger BM, et al. Cellular and extracellular markers of hemangioma. Plastic and Reconstructive Surgery 2000;106(3):529-538.
10. Beilenberg DR, Bucana CD, Sanchez R, et al. Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expressionofthe endogenous angiogenesis inhibitor, IFN-beta. International Journal of Oncology 1999;14(3):401-408.
11. Takahashi K, Mulliken JB, Kozakewich HP, et al. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. The Journal of Clinical Investigation 1994;93(6):2357-2364.
12. Chang J, Most D, Bresnick S, et al. Proliferative hemangiomas: Analysis of cytokine gene expression and angiogenesis. Plastic and Reconstructive Surgery 1999;103(1):1-9.
13. Choi K, Kenedy M, Kazarov A, et al. A common precursor for hematopoietic and endothelial cells. Development 1998;125(4):725-732.
14. Ferrara N and Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438(7070):967-974.
15. Zarem HA, Edgerton MT. Induced resolution of cavernous hemangiomas following prednisolone therapy. Plast Reconstr Surg 1967;39:76-83.
16. Zweichfach BW, Shoor E, Black MM. The influence of adrenal cortex on behavior of terminal vascular bed. Ann N Y Acad Sci 1953;56:626-633.
17. Folkman J, Langer R, Linhardt R, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983;221:719-725.
18. Sasaki GH, Pang CY, Wittliff JL. Pathogenesis and treatment of infant skin strawberry hemangiomas: Clinical andinvitro studies of hormonal effects. Plast Reconstr Surg 1984 Mar;73(3):359- 370.
19. Hasan Q, Tan ST, Gush J, Peters SG, Davis PF. Steroid therapy of a proliferating hemangioma: Histochemical and molecular changes. Pediatrics 2000;105:117-121.
20. Hasan Q, Tan ST, Gush J, Davis PF. Altered mitochondrial cytochrome b gene expression during the regression of hemangioma. Plastic and Reconstructive Surgery 2001;108:1471-1476.
21. Hasan Q, Tan ST, Xu B, Davis PF. Effects of five commonly used glucocorticoids on haemangioma in vitro. Clinical and Experimental Pharmacology and Physiology 2003;30:140-144.
22. Bennett M, Fleischer A, Chamlin S, Frieden I. Oral corticosteroid use is effective for cutaneous hemangiomas. Archives of Dermatology 2001;137:1208-1213.
23. Sadan N, Wolach B. Treatment of hemangiomas of infants with high doses of prednisone. Journal of Pediatrics 1996;128:141-146.
24. Delesalle F, Staumont D, Houmany MA, et al. Pulse methyl-prednisolone therapy for threatening periocular haemangiomas of infancy. Acta Dermato Venereologica 2006;86:429-432.
25. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg 1999 Nov;104(6):1616-1623.
26. George ME, Sharma V, Jacobson J, Simon S, Nopper AJ. Adverse effects of systemic glucosteroid therapy in infants with hemangiomas. Arch Dermatol 2004 Aug;140(8):963-969.
27. Coats DK, O'Neil JW, D'Elia VJ, et al. Sub-Tenon's infusion of corticosteroids for treatment of orbital hemangiomas. Ophthalmology 2003;110:1255-1259.
28. Friling R, Axer-Siegel R, Ben-Amitai D, et al. Intralesional and sub-Tenon's infusion of corticosteroids for treatment of refractory periorbital and orbital capillary haemangioma. Eye (in press).
29. Kushner BJ. Intralesional corticosteroid injection for infantile adnexal hemangioma. American Journal of Ophthalmology 1982;93:496-506.
30. Morrell AJ, Willshaw HE. Normalization of refractive error after steroid injection for adnexal haemangiomas. British Journal of Ophthalmology 1991;75:301-305.
31. WeissAHand Kelly JP. Reappraisal ofastigmatism induced by periocular capillary hemangioma and treatment with intralesional corticosteroid injection. Ophthalmology 2008;115:390-397.
32. Egbert JE, Paul S, Engel WK, et al. High injection pressure during intralesional injection of corticosteroids into capillary hemangiomas. Archives of Ophthalmology 2001;119:677-683.
33. Shorr N, Seiff SR. Central retinal artery occlusion associated with periocular corticosteroid injection for juvenile hemangioma. Ophthalmic Surgery 1986;17:229-231.
34. Ruttum MS, Abrams GW, Harris GJ, Ellis MK. Bilateral retinal embolization associated with intralesional corticosteroid injection for capillary hemangioma of infancy. Journal of Pediatric Ophthalmology and Strabismus 1993;30:4-7.
35. Egbert JE, Schwartz GS, Walsh AW. Diagnosis and treatment of an ophthalmic artery occlusion during an intralesional injection of corticosteroid into an eyelid capillary hemangioma. American Journal of Ophthalmology 1996;121:638-642.
36. Droste PJ, Ellis FD, Sondhi N, et al. Linear subcutaneous fat atrophy after corticosteroid injection of periocular hemangiomas. American Journal of Ophthalmology 1988;105:65-69.
37. Dyment PG. Local atrophy following triamcinolone injection. Pediatrics 1970;46:136-137.
38. Sutula FC, Glover AT. Eyelid necrosis following intralesional corticosteroid injection for capillary hemangioma. Ophthalmic Surg 1987;18:103-105.
39. Weiss AH. Adrenal suppression after corticosteroid injection of periocular hemangiomas. American Journal of Ophthalmology 1989;107:518-522.
40. Ranchod TM, Frieden IJ, Fredrick DR. Corticosteroid treatment of periorbital haemangioma of infancy: A review of the evidence. British Journal of Ophthalmology 2005;89(9)1134-1138.
41. Elsas FJ, Lewis AR. Topical treatment of periocular capillary hemangioma. Strabismus 1994;31:153-156.
42. Cruz OA, Zarnegar SR, Myers SE. Treatment of periocular capillary hemangioma with topical clobetasol propionate. Ophthalmology 1995;102:2012-2015.
43. Garzon MC, Lucky AW, Hawrot A, et al. Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. Journal of the American Academy of Dermatology 2005;52:281-286.
44. Groopman JE, Gottlieb MS, Goodman J, et al. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immune deficiency syndrome. Annals of Internal Medicine 1984;100:671-676.
45. White CW, Sondheimer HM, Crouch EC, et al. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med 1989;320:1197-1200.
46. Orchard PJ, SmithCM3rd, Woods WG, et al. Treatment of haemangioendotheliomas with alpha interferon. Lancet 1989;2:565-567.
47. Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy [published erratum appears in N Engl J Med 1994;330:300
48. and N Engl J Med 1995;333:595-6].
49. N Engl J Med 1992;326:1456-1463.
50. Ricketts RR, Hatley RM, Corden BJ, et al. Interferon-alpha-2a for the treatment of complex hemangiomas of infancy and childhood. Ann Surg 1994;219:605-614.
51. Chang E, Boyd A, Nelson CC, et al. Successful treatment of infantile hemangiomas with interferon-alpha-2b. Journal of Pediatric Hematolology and Oncology 1997;19:237-244.
52. Bauman NM, Burke DK, Smith RJ. Treatment of massive or life-threatening hemangiomas with recombinant alpha (2a)-interferon. Otolaryngol Head Neck Surg 1997;117:99-110.
53. Greinwald JH Jr, Burke DK, Bonthius DJ, et al. An update on the treatment of hemangiomas in children with interferon alfa-2a. Arch Otolaryngol Head Neck Surg 1999;125:21-27.
54. Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr 1998;132:527-530.
55. MichaudA,Bauman NM, Burke DK, et al. Spastic diplegia and other motor disturbances in infants receiving interferon alfa. Laryngoscope 2004;114:1231-1236.
56. Ghadially FN. Ultrastructural Pathology on the Cell and Matrix. Crystalline Inclusions. London: Butterworth, 1988;978.
57. Adams D, Orme L, Bowers D. Vincristine treatment for complicated hemangiomas. Abstract presented at 14th International Workshop on Vascular Anomalies, Nijmegen, Netherlands, June 28, 2002.
58. Boehm DK, Kobrinsky NL. Treatment of cavernous hemangioma with vincristine. Ann Pharmacother 1993;27:981.
59. Moore J, Lee M, Garzon M, Soffer S, Kim E, Saouaf R, et al. Effective therapy of a vascular tumor of infancy with vincristine. J Pediatr Surg 2001;36:1273-1276.
60. Payarols JP, Masferrer JP, Bellvert CG. Treatment of life-threatening infantile hemangiomas with vincristine. N Engl J Med 1995;333:369.
61. Thomson K, Pinnock R,TeagueL, et al. Vincristine for the treatment of Kasabach-Merritt syndrome: recent New Zealand case experience. The New Zealand Medical Journal 2007;120(1249):1- 10.
62. Rush BF. Treatment of a giant cutaneous hemangioma by intraarterial injection of nitrogen mustard. Ann Surg 1966;164:921-923.
63. al-Rashid RA. Cyclophosphamide and radiation therapy in the treatment of hemangioendothelioma with disseminated intravascular clotting. Cancer 1971;27:364-368.
64. Alkalay AL, Puri AR, Pomerance JJ,etal. Mesenchymal hamartoma of the liver responsive to cyclophosphamide therapy: therapeutic approach. J Pediatr Surg 1985;20:125-128.
65. Castro R, Meek R, Bean C, et al. Successful treatment of a giant cavernous hemangioma with oral cyclophosphamide (Cytoxan) in an infant. Del Med J 1992;64:745-749.
66. Hurvitz SA, Hurvitz CH, Sloninsky L, Sanford MC. Successful treatment with cyclophosphamide of life-threatening diffuse hemangiomatosis involving the liver. J Pediatr Hematol Oncol 2000;22:527-532.
67. Gottschling S, Schneider G, Meyer S, et al. Two infants with life-threatening diffuse hemangiomatosis treated with cyclophosphamide. Pediatr Blood Cancer 2006;46:239-242.
68. Wilson MW, Hoehn ME, Haik BG, et al. Low-dose cyclophosphamide and interferon alfa 2a for the treatment of capillary hemangioma of the orbit. Ophthalmology 2007;114:1007-1011.
69. Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas JM Jr. Treatment of genital warts with an immune response modifier (imiquimod). J Am Acad Dermatol 1998;38:230- 239.
70. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001;44:807-813.
71. Hengee UR, Stark R. Topical imiquimod to treat intraepidermal carcinoma. Arch Dermatol 2001;137:709-711.
72. Stockfleth E, Meyer T, Benninghoff B, Christofers E. Successful treatment of actinic keratosis with imiquimod cream 5%: A report of six cases. Br J Dermatol 2001;144:1050-1053.
73. Murchinson AP, Washington CV, Soloman AR, et al. Ocular effects of imiquimod with treatment of eyelid melanoma in situ. Dermatologic Surgery 2007;33:1136-1138.
74. Leppala J, Kaarniranta K, Uusitalo H, et al. Imiquimod in the treatment of eyelid basal cell carcinoma. Acta Ophthalmol Scand 2007 Aug;85(5):566-568.
75. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000;43:S6-S11.
76. Martinez MI, Sanchez-Carpintero IS, North PE, et al. Infantile hemangioma: Clinical resolution with 5% imiquimod cream. Archives of Dermatology 2002;183(7):881-884.
77. Ho NT, Lansang P, Pope E. Topical imiquimod in the treatment of infantile hemangiomas: A retrospective study. J Am Acad Dermatol 2007 Jan;56(1):63-68.
78. Léauté-Labreèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008 Jun 12;358(24):2649-2651.
79. D'Angelo G, Lee H, Weiner RI. cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation. J Cell Biochem 1997;67:353- 366.
80. Sommers Smith SK, Smith DM. Beta blockade induces apoptosis in cultured capillary endothelial cells. In Vitro Cell Dev Biol Anim 2002;38:298-304.